Description: Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Home Page: www.gilead.com
GILD Technical Analysis
333 Lakeside Drive
Foster City,
CA
94404
United States
Phone:
650 574 3000
Officers
Name | Title |
---|---|
Mr. Daniel P. O'Day | Chairman & CEO |
Mr. Andrew D. Dickinson | Exec. VP & CFO |
Ms. Johanna Mercier | Chief Commercial Officer |
Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer |
Ms. Diane E. Wilfong | Sr. VP, Corp. Controller & Chief Accounting Officer |
Ms. Jacquie Ross C.F.A. | VP of Investor Relations |
Ms. Deborah H. Telman | Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. |
Ms. Jyoti K. Mehra | Exec. VP of HR |
Dr. Michael Quigley Ph.D. | Sr. VP of Research Biology |
Dr. Linda Slanec Higgins Ph.D. | Sr. VP & Head of External Innovation |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 13.1926 |
---|---|
Trailing PE: | 32.2348 |
Price-to-Book MRQ: | 5.3231 |
Price-to-Sales TTM: | 4.0018 |
IPO Date: | 1992-01-22 |
Fiscal Year End: | December |
Full Time Employees: | 14400 |